Independent Director 2025 Annual Performance Report
Zhongsheng Pharma Stock Code: 002317 Independent Director Performance Report
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Independent Director 2025 Annual Performance Report
To all shareholders and shareholder representatives:
As an independent director of Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Zhongsheng Pharma"), in accordance with the "Company Law," the "Administrative Measures for Independent Directors of Listed Companies," and other relevant laws, regulations, and the "Articles of Association" and the "Work System for Independent Directors," I have faithfully and diligently performed my duties, fully utilized the role of an independent director, and protected the overall interests of the Company and the legitimate rights and interests of all shareholders, especially minority shareholders.
Here is a report on my performance of independent director duties in 2025:
I. Basic Information
(I) Work Experience, Professional Background, and Concurrent Positions
I, Liu Yunguo, hold a Ph.D. from Xiamen University, was selected for the Accounting Masters Training Program by the Ministry of Finance, received special government support, and was recognized as a leading accounting talent by the Ministry of Finance. I previously served as an independent director for listed companies such as Shenzhen Xiangjiang Holdings Co., Ltd. and Guangdong Haida Group Co., Ltd. I am currently a professor and doctoral supervisor in the School of Management at Sun Yat-sen University. I also serve as an independent director for Guangzhou Haige Communication Group Co., Ltd. and Guangzhou Visionox Technology Co., Ltd. I was elected as an independent director of the ninth board of directors of Zhongsheng Pharma starting from December 29, 2025.
I meet the qualification requirements for independent directors of listed companies as stipulated by relevant laws, regulations, and regulatory rules, and have been filed and reviewed by the Shenzhen Stock Exchange.
(II) No Circumstances Affecting Independence
As an independent director of Zhongsheng Pharma, I possess the independence required by the "Administrative Measures for Independent Directors of Listed Companies," the "Shenzhen Stock Exchange Main Board Listed Company Self-Regulatory Management Guide No. 1 - Standardized Operation of Main Board Listed Companies," the "Articles of Association," and the "Work System for Independent Directors." I have conducted an independence self-assessment in accordance with regulatory rules and confirmed that I meet the applicable independence requirements for serving as an independent director of the Company. I have submitted the self-assessment results to the board of directors. The board of directors has evaluated my independence and found no circumstances that could affect my independent and objective judgment as an independent director. I have no relationship with the Company and its controlling shareholder that could hinder independent and objective judgment. I perform my duties independently and am not influenced by the controlling shareholder or other entities or individuals with related interests in the Company, and therefore, there are no circumstances affecting my independence as an independent director.
II. Overview of Annual Performance
(I) Meeting Attendance
During my tenure in 2025, I have upheld a diligent and responsible work attitude, attended board meetings on time, participated in board decision-making, and expressed clear opinions on the matters discussed. There were no instances of missing two consecutive meetings without personally attending or entrusting another independent director to attend on my behalf.